Discontinuation of Antihyperglycemic Therapy After Acute Myocardial Infarction: Medical Necessity or Medical Error?
Abstract:Background: A national Medicare database indicated that one in eight older patients with diabetes was discharged off all antihyperglycemic therapy (AHT) following acute myocardial infarction (AMI). This practice was associated with increased one-year mortality, but the reasons for stopping AHT were not known. A study was conducted to determine whether such practice might be due to medical necessity (that is, a new contraindication) or oversight—in which case a quality improvement opportunity might exist.
Methods: Some 327 diabetic patients were identified who were hospitalized with AMI during a one-year period at an academic medical center and an affiliated community hospital. Detailed chart reviews were conducted on the 217 patients with AMI as a principal diagnosis who were admitted on AHT (insulin, 81). Twenty-five patients (11.5%) were discharged off AHT, 24 (96%) of whom received some AHT in the hospital, mostly as insulin sliding scale. One patient's (4%) AHT was stopped because of a change in care goals, a second developed recurrent hypoglycemia, and a third had entirely normal in-hospital blood glucose after AHT discontinuation. The remaining 22 patients (88%) were categorized as being discharged off AHT without justification. The demographic/ clinical characteristics of those discharged on versus off AHT were similar, except for better left ventricular ejection fraction (LVEF) in the latter.
Conclusions: The percentage of diabetic patients discharged off AHT following AMI was nearly identical to that in a national database (approximately one out of eight). No clear reason for this practice could be found in nearly 90% of the cases, suggesting that it may often constitute a medical error for a growing population of diabetic patients with ischemic heart disease.
Document Type: Research Article
Publication date: September 1, 2012
More about this publication?
- Published monthly, The Joint Commission Journal on Quality and Patient Safety is a peer-reviewed publication dedicated to providing health professionals with the information they need to promote the quality and safety of health care. The Joint Commission Journal on Quality and Patient Safety invites original manuscripts on the development, adaptation, and/or implementation of innovative thinking, strategies, and practices in improving quality and safety in health care. Case studies, program or project reports, reports of new methodologies or new applications of methodologies, research studies on the effectiveness of improvement interventions, and commentaries on issues and practices are all considered.
David W. Baker, MD, MPH, FACP, executive vice president for the Division of Healthcare Quality Evaluation at The Joint Commission, is the inaugural editor-in-chief of The Joint Commission Journal on Quality and Patient Safety.
Also known as Joint Commission Journal on Quality Improvement and Joint Commission Journal on Quality and Safety
- Editorial Board
- Information for Authors
- Subscribe to this Title
- Information for Advertisers
- Reprints and Permissions
- Ingenta Connect is not responsible for the content or availability of external websites